Clinical trials: Non-Metastatic Adenocarcinoma of the Rectum
Colorectal Cancer, Triple Negative Breast Cancer, NSCLC - Adenocarcinoma
A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)
The purpose of this study was to combine the PDR001 checkpoint inhibitor with each of four agents with immunomodulatory activity to identify the doses and schedule for combination therapy and to preliminarily assess the safety…
- Trial name
- NCT02900664
- Testing
- PDR001, ACZ885, CJM112
- Where
- 23 sites in United States, Belgium and 7 more
- Volunteers
- 283 people
- Sponsor
- Novartis Pharmaceuticals
Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum
Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer
This phase I trial is studying the side effects and best dose of erlotinib hydrochloride when given together with cetuximab and to see how well they work in treating patients with advanced gastrointestinal cancer, head and neck…
- Conditions
- Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix
- Trial name
- NCT00397384
- Testing
- cetuximab, erlotinib hydrochloride, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- National Cancer Institute (NCI)
Cancer
BCX-1777 in Treating Patients With Refractory Cancer
RATIONALE: BCX-1777 may stop the growth of cancer cells by blocking the enzymes necessary for their growth. PURPOSE: Phase I trial to study the effectiveness of BCX-1777 in treating patients who have refractory cancer.
- Trial name
- NCT00073944
- Testing
- forodesine hydrochloride
- Where
- United States
- Sponsor
- BioCryst Pharmaceuticals
Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum
Vorinostat, Fluorouracil, and Leucovorin Calcium in Treating Patients With Metastatic Colorectal Cancer That Has Not Responded to Previous Treatment
RATIONALE: Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as fluorouracil and leucovorin calcium, work in different ways to stop the growth…
- Conditions
- Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Recurrent Colon Cancer, Recurrent Rectal Cancer
- Trial name
- NCT00942266
- Testing
- fluorouracil, leucovorin calcium, vorinostat
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- Roswell Park Cancer Institute
Colorectal Carcinoma, Gastric Carcinoma
A Study to Test Different Doses of BI 765049 in People With Advanced Cancer of the Colon, Rectum, Stomach, or Pancreas
This study is open to adults with advanced cancer of the colon, rectum, stomach, or pancreas, that is the cancer cannot be removed by surgery or has spread.
- Conditions
- Colorectal Carcinoma, Gastric Carcinoma, Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT06882746
- Testing
- BI 765049
- Where
- 6 sites in United States, Germany and 1 more
- Volunteers
- 14 people
- Sponsor
- Boehringer Ingelheim
Rectal Cancer, Non Metastatic Cancer
Prospective Monocentric Study Evaluating the Circulating NK Cells Phenotype and the ImmunoScore® in Patients With Non Metastatic Rectal Cancer
Until 2020, the standard treatment for rectal cancer was a combination of radiotherapy and concomitant chemotherapy based on IV or oral 5FU, with a low complete response rate.
- Trial name
- IMMUNOREC (NCT06536127)
- Testing
- Blood samples
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Institut Sainte Catherine
Rectal Adenocarcinoma, Non Metastatic
A Global, Integrated, Personalized, Stage-related, Multimodal Therapeutic Approach for Rectal Adenocarcinoma Based on Organ Sparing and Mininvasivity
A phase II, single-center, non-profit, interventional study on patients affected by rectal adenocarcinoma. Patients will be stratified into three groups based on pre-treatment clinical stage.
- Trial name
- INTERPRETE (NCT06952101)
- Testing
- Sparing Approach, experimental chemoradiotherapy, Standard Chemotherapy
- Where
- Italy
- Volunteers
- 200 people
- Sponsor
- Fondazione del Piemonte per l'Oncologia
Rectal Adenocarcinoma, Stage IIA Rectal Cancer
Regorafenib in Reducing Recurrence in Patients With Non-metastatic Rectal Cancer Who Have Completed Curative-Intent Treatment
This phase II trial studies how well regorafenib works in reducing the return of disease in patients with rectal cancer that has not spread to another place in the body who have completed curative-intent treatment.
- Conditions
- Rectal Adenocarcinoma, Stage IIA Rectal Cancer, Stage IIB Rectal Cancer, Stage IIC Rectal Cancer
- Trial name
- NCT02287727
- Testing
- Laboratory Biomarker Analysis, Regorafenib
- Where
- 3 sites in United States
- Sponsor
- Roswell Park Cancer Institute
Cancer
RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma
RATIONALE: Monoclonal antibodies, such as RAV12, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00101972
- Testing
- monoclonal antibody RAV12
- Where
- 5 sites in United States
- Volunteers
- 53 people
- Sponsor
- MacroGenics
Rectal Cancer, Adenocarcinoma of Rectum
ABCSG R07 Rectal Cancer Registry
In Austria, patients with rectal cancer that has not spread to other parts of the body are typically treated with either total neoadjuvant therapy (TNT) or immunotherapy, depending on their microsatellite status (DNA repair…
- Trial name
- ABCSG R07 RCR (NCT07780305)
- Where
- 6 sites in Austria
- Volunteers
- 600 people
- Sponsor
- Austrian Breast & Colorectal Cancer Study Group
Rectal Adenocarcinoma, Rectal Cancer
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
Rectal cancer patients who do not achieve a complete response to standard of care chemotherapy and radiation often require surgical resection as part of curative intent therapy.
- Trial name
- NCT07292298
- Testing
- High Rare Dose Rectal Brachytherapy Boost
- Where
- 3 sites in United States
- Volunteers
- 44 people
- Sponsor
- University of Colorado, Denver
Colorectal Cancer
Everolimus in Treating Patients With Advanced or Metastatic Colorectal Cancer That Did Not Respond to Previous Therapy
RATIONALE: Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00390364
- Testing
- everolimus, antiangiogenesis therapy, biopsy
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Colorectal Cancer
Combination Chemotherapy and Radiation Therapy in Treating Patients With Recurrent Metastatic Colorectal Cancer
RATIONALE: Drugs used in chemotherapy, such as oxaliplatin, fluorouracil, and leucovorin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00268333
- Testing
- fluorouracil, leucovorin calcium, oxaliplatin
- Where
- 9 sites in France
- Volunteers
- 39 people
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
Rectal Cancer, Neoplasm Metastasis
Study of Panitumumab Given First With Capecitabine and Oxaliplatin (CAPOX) and Then With Capecitabine and Radiation of the Pelvis for Treatment of Patients With Rectal Cancers That May or May Not Have Spread Beyond the Rectum
Panitumumab is a monoclonal antibody. It works by attaching to a protein called epidermal growth factor receptor found on normal and cancer cells.
- Trial name
- NCT00346099
- Testing
- Panitumumab with capecitabine and oxaliplatin (CAPOX) followed by, Panitumumab with capecitabine and radiation
- Sponsor
- NSABP Foundation Inc
Adenocarcinoma of the Pancreas, Adenocarcinoma of the Colon
Pembrolizumab In Combination With Debio 1143 In Pancreatic and Colorectal Advanced/Metastatic Adenocarcinoma
This trial is a Phase I study to be conducted in patients with non-MSI-high advanced/metastatic pancreatic ductal adenocarcinoma (PDAC) or colorectal cancer (CRC) and is divided in two Parts.
- Conditions
- Adenocarcinoma of the Pancreas, Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum
- Trial name
- CATRIPCA (NCT03871959)
- Testing
- Pembrolizumab, DEBIO1143
- Where
- France
- Volunteers
- 54 people
- Sponsor
- Centre Leon Berard
Colorectal Neoplasm
Study Using CP-751,871 In Patients With Stage IV Colorectal Cancer That Has Not Responded To Previous Anti-Cancer Treatments
This study will test if there is any survival benefit in patients with refractory metastatic colorectal cancer that receive CP-751, 871.
- Trial name
- NCT00560560
- Testing
- CP-751, 871
- Where
- 12 sites in United States, Spain and 1 more
- Volunteers
- 168 people
- Sponsor
- Pfizer
Non-Metastatic Adenocarcinoma of the Rectum
A Phase I Study of AZD6244 in Combination With Capecitabine and Radiotherapy in Locally Advanced Adenocarcinoma of the Rectum
Background: The investigational anti-cancer drug Selumetinib (AZD6244) prevents a protein found in rectal cancer from working properly, which may slow tumor growth and allow radiation and chemotherapy treatments to destroy more…
- Trial name
- NCT01134601
- Testing
- Radiation Therapy, Capecitabine, AZD6244
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- National Cancer Institute (NCI)
Colorectal Cancer
Irinotecan With or Without Panitumumab or Cyclosporine in Treating Patients With Advanced or Metastatic Colorectal Cancer That Did Not Respond to Fluorouracil
RATIONALE: Drugs used in chemotherapy, such as irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00389870
- Testing
- panitumumab, cyclosporine, irinotecan hydrochloride
- Where
- 33 sites in United Kingdom
- Volunteers
- 1,198 people
- Sponsor
- University of Leeds
Adenocarcinoma of Rectum
First Line Treatment by FOLFIRINOX for Patients With a Rectum Cancer With Synchronous Non Resectable Metastasis
The FOLFIRINOX protocol seems a promising protocol as attack treatment of a rectum cancer, with an objective response rate of about 70 %.
- Trial name
- NCT01674309
- Testing
- FOLFORINOX
- Where
- 37 sites in France
- Volunteers
- 65 people
- Sponsor
- Federation Francophone de Cancerologie Digestive
Colorectal Cancer, Metastatic Cancer
Sunitinib Malate and Combination Chemotherapy as Front-Line Therapy in Treating Patients With Metastatic Rectal Cancer That Cannot Be Removed by Surgery
RATIONALE: Sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00936832
- Testing
- FOLFIRI regimen, fluorouracil, irinotecan hydrochloride
- Where
- France
- Sponsor
- Federation Francophone de Cancerologie Digestive